Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21586420 | 0.75 | PDE10A (0.38) | TAAR1PTGDRPTGDR2HTR2AHTR2C | |
| SCHEMBL15129437 | 0.74 | P2RX7 (0.39) | P2RX7TAAR1PTGDRPTGDR2PTGER2 | |
| SCHEMBL23541662 | 0.72 | SHMT1 (0.30) | — | |
| SCHEMBL19507809 | 0.71 | CYP17A1 (0.34) | HTR2AHTR2CHTR2B | |
| SCHEMBL11705384 | 0.71 | ESR1 (0.41) | PTGDRPTGDR2 | |
| SCHEMBL18007672 | 0.70 | TAAR1 (0.42) | TAAR1PTGDRPTGDR2SCN9A | |
| SCHEMBL20932957 | 0.70 | MAP3K14 (0.33) | TAAR1 | |
| SCHEMBL19869252 | 0.70 | PTGDR2 (0.36) | TAAR1PTGDRPTGDR2 | |
| SCHEMBL16587421 | 0.69 | NPC1 (0.41) | P2RX7TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL11701220 | 0.69 | ESR1 (0.40) | PTGDRPTGDR2PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | P2RX7 22/4885TAAR1 4434/4885PTGDR 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.